In "Clinical Reasoning: A 56-year-old woman with acute vertigo and diplopia," Sharma et al. presented the case of a patient with a pontine infarct attributed to varicella-zoster virus reactivation in the setting of immunosuppression by bortezomib for treatment of light-chain amyloidosis. In response, Dr. Ambrose reminds neurologists that bortezomib, which is increasingly being used for antibody-mediated autoimmune diseases, including NMDAR encephalitis, can cause a pan-immunodeficiency. Authors Flanagan and Sharma agree that bortezomib has broad therapeutic potential, but that the risks of administration must be acknowledged.
from Neurology recent issues http://bit.ly/2RoXYbi
Comments
Post a Comment